Observational studyFrontiers in endocrinology2025
Metabolic changes after growth hormone treatment in children with growth hormone deficiency and small for gestational age: LG observational study.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Multiple clinical effects of recombinant human growth hormone therapy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Efficacy and safety of GH treatment in Japanese pediatric patients withClinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Children with growth hormone deficiency (GHD) and small for gestational age (SGA) have major growth and metabolic issues. Growth hormone (GH) treatment promotes linear growth and improves metabolic parameters. However, the long-term metabolic effects of this treatment remain unclear. This study aimed to investigate metabolic changes after GH treatment in children with GHD and SGA. Methods: The study population included 1,788 patients: 1,364 with GHD, 318 with SGA, and 106 with GHD and SGA. Data on growth and metabolic parameters, age, sex, height, weight, body mass index (BMI), and various biochemical markers before and after at least one year of GH treatment were collected from the LG observational study. Results: GH treatment was initiated at 7.3 ± 2.8 years (GHD: 7.4 ± 2.9 years; SGA: 6.6 ± 2.5 years), with an average treatment duration of 3.8 ± 1.3 years. In the GHD and SGA patient groups, the height and weight standard deviation scores (SDS) significantly increased during treatment. BMI SDS significantly decreased in the first year in both groups; the SGA group showed improvement in years 1-5. AST levels significantly decreased over the 5-year treatment period in both groups. ALT levels significantly decreased in all follow-up years in the GHD group. In both groups, total cholesterol levels decreased and random glucose levels remained within the normal range. Conclusion: These findings demonstrate a positive effect of GH treatment on growth and metabolic parameters in children with GHD and SGA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.